parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in neutrophil progenitors	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 16917

PIWIL4 in dopamine neurons, braak+0.36 (p 0.344) → +0.04 (p 0.909)receipt 16926
PIWIL4 in microglia, braak+0.39 (p 0.306) → -0.38 (p 0.309)receipt 16925

receipt 16926: PIWIL4 in dopamine neurons, braak

power: full sample +0.23 (p 0.365, n 18), 95% CI -0.27 to +0.63. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.21 (p 0.413, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.323, n 18). could be the mix.
skeptic: leave-one-out range +0.13 to +0.36, sign flips 0; without severely affected donors +0.23 (p 0.365, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PIWIL4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 16925: PIWIL4 in microglia, braak

power: full sample -0.09 (p 0.728, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.06 (p 0.800, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.02 (p 0.942, n 18). could be the mix.
skeptic: leave-one-out range -0.24 to +0.05, sign flips 2; without severely affected donors -0.09 (p 0.728, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PIWIL4 in microglia.

case closed: nothing better to follow up.

loading the receipts